EDAP Announces Positive Opinion For Reimbursement From The French National Authority For Health For HIFU Treatment Of Prostate Cancer
Portfolio Pulse from Benzinga Newsdesk
EDAP TMS SA announced that the French National Authority for Health (HAS) has issued a favorable recommendation for the reimbursement of its high-intensity focused ultrasound (HIFU) therapy for prostate cancer treatment. This is a significant step towards securing final reimbursement in France.
December 12, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EDAP TMS SA's HIFU therapy for prostate cancer has received a favorable reimbursement recommendation from the French National Authority for Health, indicating progress towards final reimbursement approval in France.
The favorable recommendation from HAS is likely to be viewed positively by investors as it represents progress in the regulatory process and could lead to increased adoption and revenue for EDAP's HIFU therapy in France. This news directly impacts EDAP and is highly relevant to the company's growth prospects in the French market.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100